Brief: Syros Presents Safety Lead-In Data From Select-Aml-1 Trial Evaluating Tamibarotene In Combination With Venetoclax And Azacitidine And Announces Plans To Initiate Randomized Portion Of Phase 2 Trial
10/12/2022 15:05
Dec 10 (Reuters) - Syros Pharmaceuticals Inc SYRS.O :
* SYROS PRESENTS SAFETY LEAD-IN DATA FROM SELECT-AML-1 TRIAL
EVALUATING TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND
AZACITIDINE AND ANNOUNCES PLANS TO INITIATE RANDOMIZED PORTION
OF PHASE 2 TRIAL
* 83% COMPOSITE COMPLETE RESPONSE RATE IN NEWLY DIAGNOSED
UNFIT
AML PATIENTS WITH RARA GENE OVEREXPRESSION
Source text for Eikon: ID:nBw1QKP7Ra
Further company coverage: SYRS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial